Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Oxycodone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 known ✓ | P35372 | 10/20 | 0.79 |
| ▸ | OPRD1 | P41143 | 9/20 | 0.79 |
| ▸ | OPRK1 | P41145 | 8/20 | 0.79 |
| ▸ | LMNA | P02545 | 2/20 | 0.77 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.77 |
| ▸ | MRGPRX2 | Q96LB1 | 1/20 | 0.77 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.64 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.64 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.64 |
| ▸ | TSHR | P16473 | 1/20 | 0.64 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.64 |
| ▸ | BLM | P54132 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Oxycodone SCHEMBL14320307 | 0.99 | OPRM1 (0.79) | OPRM1OPRD1OPRK1LMNAPDE4D | |
| Oxycodone SCHEMBL3407528 | 0.96 | OPRM1 (0.73) | OPRM1OPRD1OPRK1LMNAPDE4D | |
| Oxycodone SCHEMBL7570264 | 0.91 | OPRM1 (0.65) | OPRM1OPRD1OPRK1LMNAPDE4D | |
| Oxycodone SCHEMBL28142074 | 0.90 | OPRM1 (0.73) | OPRM1OPRD1OPRK1LMNAPDE4D | |
| Oxymorphone SCHEMBL7049111 | 0.90 | OPRM1 (0.77) | OPRM1OPRD1OPRK1LMNAPDE4D | |
| Oxycodone SCHEMBL13813558 | 0.89 | OPRM1 (1.00) | OPRM1OPRD1OPRK1LMNAALDH1A1 | |
| Oxycodone SCHEMBL8765516 | 0.89 | OPRM1 (1.00) | OPRM1OPRD1OPRK1LMNAALDH1A1 | |
| Oxycodone SCHEMBL22058352 | 0.89 | OPRM1 (1.00) | OPRM1OPRD1OPRK1LMNAALDH1A1 | |
| Oxycodone SCHEMBL22163723 | 0.89 | OPRM1 (1.00) | OPRM1OPRD1OPRK1LMNAALDH1A1 | |
| Oxycodone SCHEMBL1561081 | 0.89 | OPRM1 (1.00) | OPRM1OPRD1OPRK1LMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150064251-A1 | Tamper Resistant Dosage Form Composition And Process Of Making The Same | ExxPharma Therapeutics LLC | 2015-03-05 | — | — | US | claimed |
| US-8894987-B2 | Tamper resistant dosage forms | PURDUE PHARMACEUTICALS L.P. | 2014-11-25 | — | — | US | claimed |
| WO-2008118141-A2 | USE OF CANNABINOID MODULATING COMPOUNDS IN COMBINATION WITH OTHER THERAPEUTIC COMPOUNDS FOR ADJUNCTIVE THERAPY | ACADIA PHARMACEUTICALS INC. (US) | 2008-10-02 | — | — | WO | claimed |
| EP-3801514-A1 | METHOD OF TREATMENT WITH TRADIPITANT | Vanda Pharmaceuticals Inc. (US) | 2021-04-14 | — | — | EP | disclosed |
| EP-3694494-A1 | MODIFIED RELEASE ABUSE DETERRENT DOSAGE FORMS | Grünenthal GmbH (DE) | 2020-08-19 | — | — | EP | disclosed |
| WO-2019073028-A1 | MODIFIED RELEASE ABUSE DETERRENT DOSAGE FORMS | Grünenthal GmbH (DE) | 2019-04-18 | — | — | WO | disclosed |
| US-10137325-B2 | System and method for deactivation and disposal of a pharmaceutical dosage form | SARANGAPANI SHANTHA (US) | 2018-11-27 | — | — | US | disclosed |
| WO-2016115492-A1 | NORMALIZING MEASURED DRUG CONCENTRATIONS IN ORAL FLUIDS AND TESTING FOR POTENTIAL NON-COMPLIANCE WITH DRUG TREATMENT REGIMEN | AMERITOX, LTD. (US) | 2016-07-21 | — | — | WO | disclosed |
| US-20150265867-A1 | System and Method for Deactivation and Disposal of a Pharmaceutical Dosage Form | SARANGAPANI SHANTHA (US) | 2015-09-24 | — | — | US | disclosed |
| EP-2066331-A2 | METHODS FOR TREATING PAIN WITH REDUCED NUASEA AND VOMITING | Limerick BioPharma, Inc. (US) | 2009-06-10 | — | — | EP | disclosed |
| US-20090088394-A1 | METHODS AND COMPOSITIONS FOR THERAPEUTIC TREATMENT | ROBBINS WENDYE | 2009-04-02 | — | — | US | disclosed |
| WO-2008118141-A2 | USE OF CANNABINOID MODULATING COMPOUNDS IN COMBINATION WITH OTHER THERAPEUTIC COMPOUNDS FOR ADJUNCTIVE THERAPY | ACADIA PHARMACEUTICALS INC. (US) | 2008-10-02 | — | — | WO | disclosed |
| WO-2008070346-A9 | METHODS FOR TREATING PAIN WITH REDUCED NUASEA AND VOMITING | LIMERICK BIOPHARMA INC (US) | 2008-08-14 | — | — | WO | disclosed |
| WO-2008070346-A2 | METHODS FOR TREATING PAIN WITH REDUCED NUASEA AND VOMITING | LIMERICK BIOPHARMA, INC. (US) | 2008-06-12 | — | — | WO | disclosed |
| EP-1817023-A2 | METHODS AND COMPOSITIONS FOR TREATING PAIN | Limerick Neurosciences, Inc. (US) | 2007-08-15 | — | — | EP | disclosed |
| US-20070087977-A1 | METHODS AND COMPOSITIONS FOR TREATING PAIN | LIMERICK BIOPHARMA, INC. | 2007-04-19 | — | — | US | disclosed |
| WO-2006055672-A2 | METHODS AND COMPOSITIONS FOR TREATING PAIN | LIMERICK NEUROSCIENCES, INC. (US) | 2006-05-26 | — | — | WO | disclosed |
| US-20060111307-A1 | Methods and compositions for treating pain | LIMERICK NEUROSCIENCES, INC. | 2006-05-25 | — | — | US | disclosed |
| US-20060111308-A1 | Methods and compositions for therapeutic treatment | LIMERICK NEUROSCIENCES, INC. | 2006-05-25 | — | — | US | disclosed |
| US-4379789-A | SUPROFEN AND A CENTRALLY ACTING ANALGESIC | ORTHO PHARMACEUTICAL CORPORATION (US) | 1983-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060111307-A1 | Methods and compositions for treating pain | PGF, FABP7, ALPP | OPRM1 80/4885OPRD1 250/4885OPRK1 35/4885 |
| US-20070087977-A1 | METHODS AND COMPOSITIONS FOR TREATING PAIN | PGF, FABP7, ALPP | OPRM1 80/4885OPRD1 250/4885OPRK1 35/4885 |
| US-20090088394-A1 | METHODS AND COMPOSITIONS FOR THERAPEUTIC TREATMENT | PGF, FABP7, ALPP | OPRM1 618/4885OPRD1 1436/4885OPRK1 524/4885 |
| US-20060111308-A1 | Methods and compositions for therapeutic treatment | PGF, FABP7, ALPP | OPRM1 618/4885OPRD1 1436/4885OPRK1 524/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.